Phase 2
Completed N=30
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Breast Neoplasm
Source: ClinicalTrials.gov NCT00270894 ↗
Enrolled (actual)
30
Serious AEs
13.3%
Results posted
Mar 2012
Primary outcomePrimary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Summary
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of the following medications given every two weeks in HER2 positive breast cancer patients:
* trastuzumab (Herceptin)
* epirubicin (Ellence)
* cyclophosphamide (Cytoxan)
* docetaxel (Taxotere)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule |
60 | — |
| PRIMARY Frequency of Grade 3 or 4 Hematologic and Nonhematologic Toxicities |
2; 11; 0; 0 | — |
| SECONDARY Pathologic Response |
16; 9; 3 | — |
| SECONDARY Clinical Response Prior to Surgery |
20; 5; 2 | — |
| SECONDARY Left Ventricular Ejection Fraction (LVEF) |
63.55; 61.94; 56.88; 57.68; 58.15; 59.38 | — |
| SECONDARY Progression-free Survival (PFS) |
NA | — |
| SECONDARY Overall Survival (OS) |
NA | — |
Eligibility Criteria
Inclusion Criteria
- Non-pregnant females =/> 18 years of age
- Non-inflammatory breast cancer stage IIA - IIIC or high risk node negative
- Core biopsy of breast demonstrating invasive cancer and documented ER/PgR receptor status
- Normal cardiac function and adequate hematologic function
- Human epidermal growth factor receptor 2 protein (HER2) positive
- No evidence of metastatic disease
- ECOG Performance Status 0 - 1
- Women of childbearing potential must agree to using effective contraception while on treatment and for at least 3 months post-treatment
Exclusion Criteria
- Treated with other investigational drugs within 30 days
- Uncontrolled intercurrent disease or active infection
- Known sensitivity to e. coli-derived proteins or polysorbate 80
- Psychiatric illness or social situation that would limit study compliance
- Pre-existing peripheral neuropathy > Grade 1
- Cancer within 5 years of screening with the exception of surgically cured nonmelanomatous skin cancer; in-situ carcinoma of the cervix; or in-situ carcinoma of the breast
- Bilateral synchronous breast cancer
- Inflammatory breast cancer
- Women who are pregnant or breast feeding
Data sourced from ClinicalTrials.gov (NCT00270894). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.